Evalyn E.A.P. Mulder

Ms. Evalyn E.A.P. Mulder

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
EMEvalyn E.A.P. Mulder
Evalyn E.A.P. Mulder
JDJ.T. Dwarkasing
J.T. Dwarkasing
DTD. Tempel
D. Tempel
ASA. van der Spek
A. van der Spek
LBL. Bosman
L. Bosman
LHL.M. Hollestein
L.M. Hollestein
Background The Clinicopathological and Gene Expression Profile (CP‐GEP) model was developed to accurately identify patients with T1‐T3 primary cutaneous melanoma at low risk for nodal metastasis. Objective To validate the CP‐GEP model in an independent Dutch cohort of melanoma patients. Methods Patients (aged ≥18 years) with primary cutaneous melanoma who underwent sentinel lymph node biopsy (SLNB) between 2007‐2017 at the Erasmus Medical Centre Cancer Institute were eligible. The CP‐GEP model combines clinicopathological features (age and Breslow thickness) with the expression of eight target genes involved in melanoma metastasis (ITGB3/PLAT/SERPINE2/GDF15/TGFBR1/ LOXL4/IL8/MLANA). Using the pathology result of SLNB as gold standard, performance measures of the CP‐GEP model were calculated, resulting in CP‐GEP high risk or low risk for nodal metastasis. Results In total, 210 patients were included in the study. Most patients presented with T2 (n=94,45%) or T3 (n=70,33%) melanoma. Of all patients, 27% (n=56) had a positive SLNB, with nodal metastasis in 0%, 30%, 54%, and 16% of T1, T2, T3, and T4 melanoma patients, respectively. Overall, the CP‐GEP model had a negative predictive value (NPV) of 90.5% (95% confidence interval [CI]77.9‐96.2), with an NPV of 100% (95%CI:72.2–100) in T1, 89.3% (95%CI:72.8‐96.3) in T2, and 75.0% (95%CI:30.1‐95.4) in T3 melanomas. The CP‐GEP indicated high risk in all T4 melanomas. Conclusions The CP‐GEP model is a non‐invasive and validated tool that accurately identified patients with primary cutaneous melanoma at low risk for nodal metastasis. In this validation cohort, the CP‐GEP model has shown potential to reduce SLNB procedures in melanoma patients

9 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EMEvalyn E.A.P. Mulder
Evalyn E.A.P. Mulder
IJIva Johansson
Iva Johansson
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
DTDennie Tempel
Dennie Tempel
BRBarbara Rentroia-Pacheco
Barbara Rentroia-Pacheco
Roger Olofsson BaggeRoger Olofsson Bagge
Roger Olofsson Bagge
Background: The current standard of care for patients without sentinel node (SN) metastasis (i.e., stage I–II melanoma) is watchful waiting, while >40% of patients with stage IB–IIC will eventually present with disease recurrence or die as a result of melanoma. With the prospect of adjuvant therapeutic options for patients with a negative SN, we assessed the performance of a clinicopathologic and gene expression (CP-GEP) model, a model originally developed to predict SN metastasis, to identify patients with stage I–II melanoma at risk of disease relapse. Methods: This study included patients with cutaneous melanoma ≥18 years of age with a negative SN between October 2006 and December 2017 at the Sahlgrenska University Hospital (Sweden) and Erasmus MC Cancer Institute (The Netherlands). According to the CP-GEP model, which can be applied to the primary melanoma tissue, the patients were stratified into high or low risk of recurrence. The primary aim was to assess the 5-year recurrence-free survival (RFS) of low- and high-risk CP-GEP. A secondary aim was to compare the CP-GEP model with the EORTC nomogram, a model based on clinicopathological variables only. Results: In total, 535 patients (stage I–II) were included. CP-GEP stratification among these patients resulted in a 5-year RFS of 92.9% (95% confidence interval (CI): 86.4–96.4) in CP-GEP low-risk patients (n = 122) versus 80.7% (95%CI: 76.3–84.3) in CP-GEP high-risk patients (n = 413; hazard ratio 2.93 (95%CI: 1.41–6.09), p < 0.004). According to the EORTC nomogram, 25% of the patients were classified as having a ‘low risk’ of recurrence (96.8% 5-year RFS (95%CI 91.6–98.8), n = 130), 49% as ‘intermediate risk’ (88.4% 5-year RFS (95%CI 83.6–91.8), n = 261), and 26% as ‘high risk’ (61.1% 5-year RFS (95%CI 51.9–69.1), n = 137). Conclusion: In these two independent European cohorts, the CP-GEP model was able to stratify patients with stage I–II melanoma into two groups differentiated by RFS.

13 November 2021 in ESMO Open
Verified
Journal Article
Open access
EMEvalyn E.A.P. Mulder
Evalyn E.A.P. Mulder
LSL. Smit
L. Smit
DGD.J. Grünhagen
D.J. Grünhagen
CVC. Verhoef
C. Verhoef
SSS. Sleijfer
S. Sleijfer
CGC.A. Uyl-De Groot
C.A. Uyl-De Groot
The introduction of adjuvant systemic treatment has significantly improved recurrence-free survival in patients with resectable high-risk melanoma. Adjuvant treatment with immune checkpoint inhibitors and targeted therapy, however, substantially impacts health care budgets, while the number of patients with melanoma who are treated in the adjuvant setting is still increasing. To evaluate the socioeconomic impact of the three adjuvant treatments, a cost-effectiveness analysis (CEA) was carried out. Data were obtained from the three pivotal registration phase III clinical trials on the adjuvant treatment of patients with resected high-risk stage III in melanoma (KEYNOTE-054, CheckMate 238, and COMBI-AD). For this CEA, a Markov model with three health states (no evidence of disease, recurrent/progressive disease, and death) was applied. From a societal perspective, different adjuvant strategies were compared according to total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. To evaluate model uncertainty, sensitivity analyses (deterministic and probabilistic) were carried out. In the adjuvant setting, total costs (per patient) were €168 826 for nivolumab, €194 529 for pembrolizumab, and €211 110 for dabrafenib-trametinib. These costs were mainly determined by drug acquisition costs, whereas routine surveillance costs varied from €126 096 to €134 945. Compared with routine surveillance, LYs improved by approximately 1.41 for all therapies and QALYs improved by 2.02 for immune checkpoint inhibitors and 2.03 for targeted therapy. This resulted in incremental cost-effectiveness ratios of €21 153 (nivolumab), €33 878 (pembrolizumab), and €37 520 (dabrafenib-trametinib) per QALY gained. This CEA compared the three EMA-approved adjuvant systemic therapies for resected stage III melanoma. Adjuvant treatment with nivolumab was the most cost-effective, followed by pembrolizumab. Combination therapy with dabrafenib-trametinib was the least cost-effective. With the increasing number of patients with high-risk melanoma who will be treated with adjuvant treatment, there is an urgent need to reduce drug costs while developing better prognostic and predictive tools to identify patients who will benefit from adjuvant treatment.

26 October 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
RSRobert C. Stassen
Robert C. Stassen
EMEvalyn E.A.P. Mulder
Evalyn E.A.P. Mulder
AMAntien Mooyaart
Antien Mooyaart
AFAnne Brecht Francken
Anne Brecht Francken
JHJos van der Hage
Jos van der Hage
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
Sentinel lymph node biopsy (SLNB) is recommended for patients with >pT1b cutaneous melanoma, and should be considered and discussed with patients diagnosed with pT1b cutaneous melanoma for the purpose of staging, prognostication and determining eligibility for adjuvant therapy. Previously, the clinicopathologic and gene expression profile (CP-GEP, Merlin Assay®) model was developed to identify patients who can forgo SLNB because of a low risk for sentinel node metastasis. The aim of this study was to evaluate the clinical use and implementation of the CP-GEP model in a prospective multicenter study in the Netherlands. Both test performance and feasibility for clinical implementation were assessed in 260 patients with T1-T4 melanoma. The CP-GEP model demonstrated an overall negative predictive value of 96.7% and positive predictive value of 23.7%, with a potential SLNB reduction rate of 42.2% in patients with T1-T3 melanoma. With a median time of 16 days from initiation to return of test results, there was sufficient time left before the SLNB was performed. Based on these outcomes, the model may support clinical decision-making to identify patients who can forgo SLNB in clinical practice.

21 September 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
EMEvalyn E.A.P. Mulder
Evalyn E.A.P. Mulder
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
SSStefan Sleijfer
Stefan Sleijfer
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot
AVAstrid A.M. van der Veldt
Astrid A.M. van der Veldt

7 February 2022 in Annals of Diagnostic Pathology
Verified
Journal Article
Open access
EMEvalyn E.A.P. Mulder
Evalyn E.A.P. Mulder
DVDaniëlle Verver
Daniëlle Verver
TKThom van der Klok
Thom van der Klok
CWCalvin Jay de Wijs
Calvin Jay de Wijs
TBThierry P.P. van den Bosch
Thierry P.P. van den Bosch
SKSenada Koljenović
Senada Koljenović
Patients with cutaneous melanoma and a positive sentinel node (SN) are currently eligible for adjuvant treatment with targeted therapy and immune checkpoint inhibitors. Near-infrared (NIR) fluorescence imaging could be an alternative and less invasive tool for SN biopsy to select patients for adjuvant treatment. One potential target for NIR is the mesenchymal-epithelial transition factor (MET). This study aimed to assess MET immunoreactivity in positive SNs and to evaluate its potential diagnostic, prognostic and therapeutic value. In this retrospective study, positive SN samples from patients with primary cutaneous melanoma were collected to assess MET immunoreactivity. To this end, paraffin-embedded SNs were stained for MET (monoclonal antibody D1C2). A 4-point Histoscore was used to determine cytoplasmic and membranous immunoreactivity (0 negative/1 weak/2 moderate/3 strong). Samples were considered positive when ≥10% of the cancer cells showed MET expression (staining intensity ≥1). Patient and clinicopathological characteristics were used for descriptive statistics, binary logistic regression, and survival analyses. Positive MET immunohistochemistry was observed in 24 out of 37 samples (65%). No statistically significant associations were found between MET positivity and the following prognostic factors: Breslow thickness (P = 0.961), ulceration (P = 1.000), and SN tumor burden (P = 0.792). According to MET positivity, Kaplan-Meier curves showed no significant differences in survival. This exploratory study found no evidence to support MET immunoreactivity in positive SNs as a possible diagnostic or prognostic indicator in patients with melanoma.